EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC—A Possible Path Forward

L C Harshman, C G Drake, N B Haas, J Manola, M Puligandla, S Signoretti, D Cella, R T Gupta, R Bhatt, E Van Allen, P Lara, T K Choueiri und 9 weitere

Kidney Cancer · 2017

DOI: 10.3233/kca-170010 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Kidney Cancer, 2017. Verfasst von L C Harshman und 20 weiteren Autor:innen. Beteiligte Einrichtung: Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In 2017, there is no adjuvant systemic therapy proven to increase overall survival in non-metastatic renal cell carcinoma (RCC). The anti-PD-1 antibody nivolumab improves overall survival in metastatic treatment refractory RCC and is generally tolerable. Mouse solid tumor models have revealed a benefit with a short course of neoadjuvant PD-1 blockade compared to adjuvant therapy. Two ongoing phase 2 studies of perioperative nivolumab in RCC patients have shown preliminary feasibility and safety with no surgical delays or complications. The recently opened PROSPER RCC trial (A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy; EA8143) will examine if the addition of perioperative nivolumab to radical or partial nephrectomy can improve clinical outcomes in patients with high risk localized and locally advanced RCC. With the goal of increasing cure and recurrence-free survival (RFS) rates in non-metastatic RCC, we are executing a three-pronged, multidisciplinary approach of presurgical priming with nivolumab followed by resection and adjuvant PD-1 blockade. We plan to enroll 766 patients with clinical stage ≥T2 or node positive M0 RCC of any histology in this global, randomized, unblinded, phase 3 National Clinical Trials Network study. The investigational arm will receive two doses of nivolumab 240 mg IV prior to surgery followed by adjuvant nivolumab for 9 months. The control arm will undergo the current standard of care: surgical resection followed by observation. Patients are stratified by clinical T stage, node positivity, and histology. The trial is powered to detect a 14.4% absolute benefit in the primary endpoint of RFS from the ASSURE historical control of 55.8% to 70.2% at 5 years (HR = 0.70). The study is also powered to detect a significant overall survival benefit (HR 0.67). Key safety, feasibility, and quality of life endpoints are incorporated. PROSPER RCC exemplifies team science with a host of planned correlative work to investigate the impact of the baseline immune milieu and changes after neoadjuvant priming on clinical outcomes.

Schlagwörter

Stichwörter der Autor:innen

EA8143PD-1 blockadePROSPER RCCRenal cell carcinomaadjuvantneoadjuvantnephrectomynivolumabprimingrecurrence-free survival

Autor:innen und Institutionen

  • Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Division of Hematology/Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA.
  • Division of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
  • Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
  • Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Zitieren

APA

Harshman, L. C., Drake, C. G., Haas, N. B., Manola, J., Puligandla, M., Signoretti, S., Cella, D., Gupta, R. T., Bhatt, R., Van Allen, E., Lara, P., Choueiri, T. K., Kapoor, A., Heng, D. Y. C., Shuch, B., Jewett, M., George, D., Michaelson, D., Carducci, M. A., …, & Allaf, M. (2017). Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC—A Possible Path Forward. Kidney Cancer. https://doi.org/10.3233/kca-170010

Vancouver

Harshman LC, Drake CG, Haas NB, Manola J, Puligandla M, Signoretti S, et al. Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC—A Possible Path Forward. Kidney Cancer. 2017. doi:10.3233/kca-170010

BibTeX
@article{Harshman2017,
  author = {Harshman, L C and Drake, C G and Haas, N B and Manola, J and Puligandla, M and Signoretti, S and Cella, D and Gupta, R T and Bhatt, R and Van Allen, E and Lara, P and Choueiri, T K and Kapoor, A and Heng, D Y C and Shuch, B and Jewett, M and George, D and Michaelson, D and Carducci, M A and McDermott, D and Allaf, M},
  title = {Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC—A Possible Path Forward},
  journal = {Kidney Cancer},
  year = {2017},
  doi = {10.3233/kca-170010}
}
Kostenlos starten →